Purpose. In a previous series of 25 human osteosarcoma samples studied for MYC gene amplification, we Results. Three out of five patients (60%) with pagetic osteosarcoma showed MYC gene amplification, whereas it was present in only 5/53 patients (9.4%) with primary osteosarcoma. The incidence of MYC amplification in pagetic osteosarcoma was thus significantly higher than that in primary osteosarcoma (p 0.016). Discussion. The finding that MYC gene amplification may be more common in pagetic than primary osteosarcoma warrants further study and suggests pathogenetic differences between primary osteosarcomas and those arising in the setting of Paget's disease. Three of the four pagetic osteosarcomas from the present study were previously shown to be immunoreactive for p53, suggesting that p53 mutation may also be a frequent genetic lesion in these tumors.
Introduction
Paget's disease is a benign but precancerous condition affecting the mesenchymal cells of bones. Of the secondary sarcomas arising in Paget's disease of bone, osteosarcomas (pagetic osteosarcomas) are by far the most common and make up a substantial proportion of osteosarcomas of late adulthood. They represent an infrequent but highly lethal complication of Paget (Table 1) .
In previous studies, including some of these cases, we found that 3/4 pagetic osteosarcomas showed p53 over-expression, but none showed amplification of MDM2 (Table 1) .6
Clinical features such as sex and primary site were Case 4 also had a history of Paget's disease of the nipple due to extensive underlying intraductal carcinoma, representing a rare coincidence of these two eponymous conditions.
Discussion
The MYC proto-oncogene, which maps to chromosome band 8q24, encodes a transcription factor containing dimerization motifs (helix-loop-helix (HLH) and leucine zipper (LZ)). 7 Normally, MYC dimerizes with another HLH/LZ protein, MAX, and interacts with promoters containing the sequence CACGTG. The spectrum of genes whose transcription is physiologically regulated by MYC is a subject of active study. At the cellular level, .MYC is known to drive cell proliferation in response to extracellular signals and to promote apoptosis in proliferating cells upon withdrawal of the same signals. 7 Recently, the cell cycle phosphatase CDC25 has been identified as a direct target of transcriptional activation by MYC, providing the first clear link between MYC deregulation and cell cycle activation. 8 The present study of frozen tumor samples of pagetic and non-pagetic osteosarcomas suggests that MYC gene amplification is a common molecular genetic alteration in pagetic osteosarcoma compared to its low incidence in sporadic osteosarcoma. To our knowledge, this is the first study of molecular genetic alterations in pagetic osteosarcomas.
That the MYC proto-oncogene (formerly c-myc) plays an important role in osteosarcoma has been noted in various animal models and osteosarcoma 9 cell lines, usually in the form of amplification. 2 In the murine SEWA osteosarcoma cell line, tumorigenicity is proportional to the degree of MYC gene amplification. 13 In addition to the potential biological significance of MYC gene amplification, its presence may also be relevant clinically. In some tumor types, the presence of amplification of specific genes predicts a poorer prognosis. 17'18 Evidence is now accumulating that, likewise, MYC gene amplification is associated with poorer prognosis in musculoskeletal sarcomas including osteosarcomas. 16'19 Correspondingly, in some human osteosarcoma cell lines, MYC gene amplification is associated with higher growth rate. 2'1 Finally, in two cases of pagetic osteosarcoma, we found a coincidence of MYC amplification and p53 over-expression (indicative of p53 point mutation), in contrast to a previous study 22 of these two alterations in sarcomas.
